

Glioma

Recurrent

High Grade

Pre- Avastin

Surgical Procedural
Candidates

BRAF Mutation

FGFR1-3
Alteration

[BRN0048](#)
[Phase I, First-In-Human, Multicenter, Open-Label Study of ABM-1310 Administered Orally in Adult Patients with Advanced Solid Tumors](#)

PI: Nagpal
ABM Therapeutics, Inc.

BRN0056
Phase I/II Dose-Escalation Study of Candidate GBM Vaccine VBI-1901 with Subsequent Extension of Optimal Dose in Recurrent GBM Subjects

PI: Nagpal
VBI Vaccines Inc.

BRN0054
Phase II Pemigatinib in Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

PI: Lim
Incyte Corporation

BRN0042
Phase II/III Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM

PI: Recht
Pending

[CCT5061](#)
[Phase I Locoregionally \(LR\) Delivered Autologous B7-H3 Chimeric Antigen Receptor T Cells \(B7-H3CART\) in Recurrent Glioblastoma Multiforme \(GBM\)](#)

PI: Thomas
Stanford University

BRN0046
[Phase I Anti-Tim-3 in Combination with Anti-PD-1 and SRS in Recurrent GBM](#)

PI: Lim
Johns Hopkins University

BRN0045
[Phase I/II Exablate Type 2 for BBBD With Microbubble Resonators in Tx of rGBM in Carboplatin Mono Treatment](#)

PI: Nagpal
InSightec, Inc.

BRN0049
Phase Ib Nivolumab or the Combination Nivolumab + Ipilimumab in Surgically Accessible Glioblastoma

PI: Lim
Pending

KEY

Pending

Open for Enrollment

Observational Study

Optional Path

Trial Posting

Enrollment on Hold

Extension Study

Immunotherapy